首页> 外文OA文献 >Diagnosis of autosomal dominant polycystic kidney disease using efficient PKD1 and PKD2 targeted next-generation sequencing
【2h】

Diagnosis of autosomal dominant polycystic kidney disease using efficient PKD1 and PKD2 targeted next-generation sequencing

机译:使用有效的pKD1和pKD2靶向下一代测序诊断常染色体显性多囊肾病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Molecular diagnostics of autosomal dominant polycystic kidney disease (ADPKD) relies on mutation screening of PKD1 and PKD2, which is complicated by extensive allelic heterogeneity and the presence of six highly homologous sequences of PKD1. To date, specific sequencing of PKD1 requires laborious long-range amplifications. The high cost and long turnaround time of PKD1 and PKD2 mutation analysis using conventional techniques limits its widespread application in clinical settings. We performed targeted next-generation sequencing (NGS) of PKD1 and PKD2. Pooled barcoded DNA patient libraries were enriched by in-solution hybridization with PKD1 and PKD2 capture probes. Bioinformatics analysis was performed using an in-house developed pipeline. We validated the assay in a cohort of 36 patients with previously known PKD1 and PKD2 mutations and five control individuals. Then, we used the same assay and bioinformatics analysis in a discovery cohort of 12 uncharacterized patients. We detected 35 out of 36 known definitely, highly likely, and likely pathogenic mutations in the validation cohort, including two large deletions. In the discovery cohort, we detected 11 different pathogenic mutations in 10 out of 12 patients. This study demonstrates that laborious long-range PCRs of the repeated PKD1 region can be avoided by in-solution enrichment of PKD1 and PKD2 and NGS. This strategy significantly reduces the cost and time for simultaneous PKD1 and PKD2 sequence analysis, facilitating routine genetic diagnostics of ADPKD.
机译:常染色体显性遗传性多囊肾疾病(ADPKD)的分子诊断依赖于PKD1和PKD2的突变筛选,该过程因广泛的等位基因异质性和PKD1的六个高度同源序列而复杂化。迄今为止,PKD1的特异性测序需要费力的远距离扩增。使用常规技术进行的PKD1和PKD2突变分析的高成本和较长的周转时间限制了其在临床环境中的广泛应用。我们进行了PKD1和PKD2的靶向下一代测序(NGS)。通过与PKD1和PKD2捕获探针进行溶液内杂交来富集合并的条形码DNA患者库。使用内部开发的管道进行生物信息学分析。我们在36名先前已知PKD1和PKD2突变的患者以及5名对照个体中验证了该测定方法。然后,我们在12名未表征患者的发现队列中使用了相同的测定法和生物信息学分析。在验证队列中,我们从36个已知的,高度可能的和可能的致病性突变中检测出35个,包括两个大的缺失。在发现队列中,我们在12名患者中的10名患者中检测到11种不同的致病突变。这项研究表明,可以通过溶液内富集PKD1和PKD2以及NGS来避免重复PKD1区域繁琐的长距离PCR。该策略显着降低了同时进行PKD1和PKD2序列分析的成本和时间,从而促进了ADPKD的常规遗传诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号